Sergio Rodriguez Labra

Sergio Rodriguez Labra

Auto-generated profile, based on publicly available information

Sergio Rodriguez Labra

Department of Chemistry and Department of Molecular Medicine, The Scripps Research Institute (TSRI), La Jolla, CA 92037

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2024 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
DTDorit Trudler
Dorit Trudler
SGSwagata Ghatak
Swagata Ghatak
MBMichael Bula
Michael Bula
JPJames Parker
James Parker
MTMaria Talantova
Maria Talantova
Stuart LiptonStuart Lipton
Stuart Lipton
MEF2C is a critical transcription factor in neurodevelopment, whose loss-of-function mutation in humans results in MEF2C haploinsufficiency syndrome (MHS), a severe form of autism spectrum disorder (ASD)/intellectual disability (ID). Despite prior animal studies of MEF2C heterozygosity to mimic MHS, MHS-specific mutations have not been investigated previously, particularly in a human context as hiPSCs afford. Here, for the first time, we use patient hiPSC-derived cerebrocortical neurons and cerebral organoids to characterize MHS deficits. Unexpectedly, we found that decreased neurogenesis was accompanied by activation of a micro-(mi)RNA-mediated gliogenesis pathway. We also demonstrate network-level hyperexcitability in MHS neurons, as evidenced by excessive synaptic and extrasynaptic activity contributing to excitatory/inhibitory (E/I) imbalance. Notably, the predominantly extrasynaptic (e)NMDA receptor antagonist, NitroSynapsin, corrects this aberrant electrical activity associated with abnormal phenotypes. During neurodevelopment, MEF2C regulates many ASD-associated gene networks, suggesting that treatment of MHS deficits may possibly help other forms of ASD as well.

30 September 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
LYLeonard Yoon
Leonard Yoon
RBRachel C. Botham
Rachel C. Botham
AVAdriaan Verhelle
Adriaan Verhelle
CCChristian M. Cole
Christian M. Cole
ETEe Phie Tan
Ee Phie Tan
FRFulvio Reggiori
Fulvio Reggiori
Summary: Autophagy-lysosomal impairment is an early and prominent feature of neurodegeneration. Autophagy activation reduces protein aggregates and lipid level abnormalities. We performed a high-content imaging-based screen assessing 940,000 small molecules to identify those that reduce lipid droplet numbers. Of 77 validated, structurally diverse hits, 24 increased autophagy flux reporter activity, consistent with accelerated lipid droplet clearance by lipophagy. Of these, we show that CCT020312 activates autophagy independently of mammalian target of rapamycin (mTOR) inhibition, to avoid immunosuppression. CCT020312 reduced insoluble phosphorylated tau levels and tau-mediated neuronal stress vulnerability, as well as reducing intracellular Aβ levels within directly induced neurons bearing epigenetic marks of aging derived from Alzheimer’s patient fibroblasts. Moreover, CCT020312 cleared mutant prion protein aggregates and normalized trafficking deficiencies in axons of a cellular model of familial prion disease. Autophagy is widely considered a promising strategy to attenuate neurodegeneration, and here we introduce a strategy to discover new pharmacology.

27 January 2026 in Advanced Science
Verified
Journal Article
Open access
SLSergio R. Labra
Sergio R. Labra
JCJadon Compher
Jadon Compher
APAkhil Prabhavalkar
Akhil Prabhavalkar
MAMireya Almaraz
Mireya Almaraz
CKClaudia Cedeño Kwong
Claudia Cedeño Kwong
Stuart LiptonStuart Lipton
Stuart Lipton
Alzheimer's disease (AD) is the leading cause of dementia worldwide. Nevertheless, its cellular and molecular mechanisms remain incompletely understood, partially due to inadequate disease models. To illuminate early changes in AD, we developed a cerebrocortical organoid (CO) model with improved methodology. Our COs produce excitatory and inhibitory neurons alongside glia, utilizing established isogenic wild‐type and diseased human induced pluripotent stem cells (hiPSCs) carrying heterozygous familial AD mutations in PSEN1 ΔE9 /WT, PSEN1 M146V /WT, or APP Swe /WT. In addition to amyloid‐beta (Aβ) accumulation, the AD COs display time‐progressive loss of monomeric Tau, and accumulation of aggregated high‐molecular‐weight (HMW) phospho(p)‐Tau species (pT181 and pT217). They also exhibit neuronal hyperexcitability reminiscent of early electroencephalography (EEG) clinical findings and synapse loss in AD patient brains. Single‐cell RNA‐sequencing analyses of AD and WT control COs reveal significant divergent molecular abnormalities in excitatory vs. inhibitory neurons, with several pathways being upregulated in one while downregulated in the other, providing insight into AD phenotypes. Finally, we show that chronic dosing with autophagy activators, including a novel mTOR inhibitor‐independent drug candidate, prevents pathologic Aβ and HMW p‐Tau accumulation, normalizes hyperexcitability, and rescues synaptic loss in AD COs. Collectively, our results demonstrate this CO model as a useful platform for assessing early features of familial AD pathogenesis and for testing small‐molecule candidate therapeutics.

25 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
SLSergio R. Labra
Sergio R. Labra
JCJadon Compher
Jadon Compher
APAkhil Prabhavalkar
Akhil Prabhavalkar
MAMireya Almaraz
Mireya Almaraz
CKClaudia Cedeño Kwong
Claudia Cedeño Kwong
Stuart LiptonStuart Lipton
Stuart Lipton
SUMMARY: Alzheimer’s disease (AD) is the most common form of dementia worldwide. Despite extensive progress, the cellular and molecular mechanisms of AD remain incompletely understood, partially due to inadequate disease models. To illuminate the earliest changes in hereditary (familial) Alzheimer’s disease, we developed an isogenic AD cerebrocortical organoid (CO) model. Our refined methodology produces COs containing excitatory and inhibitory neurons alongside glial cells, utilizing established isogenic wild-type and diseased human induced pluripotent stem cells (hiPSCs) carrying heterozygous familial AD mutations, namely PSEN1 ΔE9/WT , PSEN1 M146V/WT , or APP swe/WT . Our CO model reveals time-progressive accumulation of amyloid beta (Aβ) species, loss of monomeric Tau, and accumulation of aggregated high-molecular-weight (HMW) phospho(p)-Tau species. This is accompanied by neuronal hyperexcitability, as observed in early human AD cases on electroencephalography (EEG), and synapse loss. Single-cell RNA-sequencing analyses reveal significant differences in molecular abnormalities in excitatory vs. inhibitory neurons, helping explain AD clinical phenotypes. Finally, we show that chronic dosing with autophagy activators, including a novel CNS-penetrant mTOR inhibitor-independent drug candidate, normalizes pathologic accumulation of Aβ and HMW p-Tau, normalizes hyperexcitability, and rescues synaptic loss in COs. Collectively, our results demonstrate these COs are a useful human AD model suitable for assessing early features of familial AD etiology and for testing drug candidates that ameliorate or prevent molecular AD phenotypes.

29 October 2024 in IEEE Transactions on Computational Biology and Bioinformatics
Verified
Journal Article
Closed access
HZHaosheng Zhou
Haosheng Zhou
WLWei Lin
Wei Lin
SLSergio R. Labra
Sergio R. Labra
Stuart LiptonStuart Lipton
Stuart Lipton
JEJeremy A. Elman
Jeremy A. Elman
ARAaditya V. Rangan
Aaditya V. Rangan
Many traditional methods for analyzing gene-gene relationships focus on positive and negative correlations, both of which are a kind of ‘symmetric’ relationship. Biclustering is one such technique that typically searches for subsets of genes exhibiting correlated expression among a subset of samples. However, genes can also exhibit ‘asymmetric’ relationships, such as ‘if-then’ relationships used in boolean circuits. In this paper we develop a very general method that can be used to detect biclusters within gene-expression data that involve subsets of genes which are enriched for these ‘boolean-asymmetric’ relationships (BARs). These BAR-biclusters can correspond to heterogeneity that is driven by asymmetric gene-gene interactions, e.g., reflecting regulatory effects of one gene on another, rather than more standard symmetric interactions. Unlike typical approaches that search for BARs across the entire population, BAR-biclusters can detect asymmetric interactions that only occur among a subset of samples. We apply our method to a single-cell RNA-sequencing data-set, demonstrating that the statistically-significant BARbiclusters indeed contain additional information not present within the more traditional ‘boolean-symmetric’-biclusters. For example, the BAR-biclusters involve different subsets of cells, and highlight different gene-pathways within the data-set. Moreover, by combining the boolean-asymmetric- and boolean-symmetricsignals, one can build linear classifiers which outperform those built using only traditional boolean-symmetric signals.

31 January 2025
Verified
Book Chapter
Closed access
SLSergio Rodriguez Labra
Sergio Rodriguez Labra